Company intelligence / Profile preview

Crospon

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Crospon’s flagship product, the EndoFLIP imaging system, received FDA clearance in December 2009 and has been commercialized in the US, Canada, Australia, and Europe. It provides real-time measurement of esophageal contractility and lumen geometry during endoscopy or bariatric surgery. The company also developed EsoFLIP for dilation procedures and Janisys for transdermal drug delivery. Clinical adoption has been strong among gastroenterologists and bariatric surgeons.

Therapeutic areas: Gastroenterology
Modalities: Device (Endolumenal Functional Lumen Imaging Probe, EndoFLIP)Device (EsoFLIP balloon catheter)Device (Janisys microneedle-based transdermal drug delivery system)
Industry: Medical Imaging

Beyond the preview

Go deeper on Crospon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crospon.

Explore the full profile